BMP10

A gene on chromosome 2p13.3, bone morphogenetic protein-10, which plays a key role in trabeculation of the embryonic heart, acting via receptor serine/ threonine kinases.

Mentioned in ?

bone morphogenetic protein-10

References in periodicals archive ?

BMP1 - 8p21; BMP2 - 20p12; BMP3 - 14p22; BMP4 - 14q22-q23; BMP5 - 6p12,1; BMP6 - 6p12,1; BMP7 - 20q13; BMP8a - 1p35p32; BMP8b - 1p35-p32; BMP10 - 2p14; BMP15 - Xp11,2.

Defectos del tubo neural y acido folico: patogenia, metabolismo y desarrollo embriologico. Revision de la literatura

Dalantercept (ACE-041) is an investigational protein therapeutic that inhibits angiogenesis by preventing BMP9 and BMP10, proteins in the TGF- superfamily, from interacting with activin receptor-like kinase 1 (ALK1), a cell-surface receptor found on proliferating vascular endothelial cells.

Acceleron Announces the Initiation of Phase 2 Clinical Trial of Dalantercept (ACE-041) in Patients with Ovarian Cancer

Dalantercept is an ALK1 receptor fusion protein that binds to BMP9 and BMP10 and inhibits their signaling through the ALK1 receptor.

Acceleron and Collaborators Present Data on Potential Biomarkers for Metastatic Breast Cancer and Head and Neck Cancer at the "2012 Markers in Cancer" Conference

ACE-041 is an ALK1 ligand trap that inhibits angiogenesis by preventing BMP9 and BMP10, members of the TGF protein superfamily, from interacting with activin receptor-like kinase 1 (ALK1), a receptor found on proliferating endothelial cells.

Acceleron's ACE-041 Combined with a VEGF Inhibitor Shows Potent Activity in Preclinical Model of VEGF-Resistant Renal Cell Carcinoma

ACE-041 is a recombinant receptor fusion protein that inhibits angiogenesis by preventing BMP9 and BMP10, proteins in the TGF superfamily, from interacting with activin receptor-like kinase 1 (ALK1), a cell-surface receptor found on proliferating endothelial cells.

Acceleron Presents Positive Results from Phase 1 Study of ACE-041 in Patients with Advanced Cancer